Cargando…

Concurrence of nivolumab‐induced interstitial lung disease and cancer invasion

Nivolumab improves overall survival rates of patients with advanced or recurrent non‐small‐cell lung cancer (NSCLC). Among immune‐related adverse events caused by nivolumab, interstitial lung disease (ILD) is a clinically serious and potentially life‐threatening toxicity, for which appropriate treat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kanai, Osamu, Nakatani, Koichi, Fujita, Kohei, Okamura, Misato, Mio, Tadashi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Ltd 2017
Materias:	Case Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5553297/ https://www.ncbi.nlm.nih.gov/pubmed/28811904 http://dx.doi.org/10.1002/rcr2.257

Ejemplares similares

Development of Mycobacterium avium Complex Lung Disease in Patients With Lung Cancer on Immune Checkpoint Inhibitors
por: Fujita, Kohei, et al.
Publicado: (2020)

Afebrile tension pyopneumothorax due to anaerobic bacteria: Fistula or gas production?
por: Kanai, Osamu, et al.
Publicado: (2021)

No need to hesitate: immune‐related neutropenia and thrombocytopenia that improved by corticosteroids
por: Kanai, Osamu, et al.
Publicado: (2021)

Acute progression of aspergillosis in a patient with lung cancer receiving nivolumab
por: Uchida, Naohiro, et al.
Publicado: (2017)

Efficacy and safety of nivolumab in non‐small cell lung cancer with preexisting interstitial lung disease
por: Kanai, Osamu, et al.
Publicado: (2018)

Incidence of Active Tuberculosis in Lung Cancer Patients Receiving Immune Checkpoint Inhibitors
por: Fujita, Kohei, et al.
Publicado: (2020)

Small cell transformation of non‐small cell lung cancer under immunotherapy: Case series and literature review
por: Imakita, Takuma, et al.
Publicado: (2021)

Small cell lung cancer transformation during immunotherapy with nivolumab: A case report
por: Imakita, Takuma, et al.
Publicado: (2017)

Retreatment with anti‐PD‐1 antibody in non‐small cell lung cancer patients previously treated with anti‐PD‐L1 antibody
por: Fujita, Kohei, et al.
Publicado: (2019)

Pleural involvement of diffuse large B-cell lymphoma mimicking malignant pleural mesothelioma
por: Ito, Takanori, et al.
Publicado: (2020)

The clinical benefits of immune checkpoint inhibitor for thymic carcinomas ∼experience of single public hospital in Japan∼
por: Uchida, Naohiro, et al.
Publicado: (2018)

Repetitive responses to nanoparticle albumin‐bound paclitaxel and carboplatin in malignant pleural mesothelioma
por: Kanai, Osamu, et al.
Publicado: (2016)

Nasogastric tube‐administered alectinib achieved long‐term survival in a crizotinib‐refractory nonsmall cell lung cancer patient with a poor performance status
por: Kanai, Osamu, et al.
Publicado: (2017)

Effect of cyclooxygenase inhibitor use on immunotherapy efficacy in non‐small cell lung cancer
por: Kanai, Osamu, et al.
Publicado: (2021)

Efficacy and safety of immune checkpoint inhibitors in patients with non‐small cell lung cancer aged 80 years or older
por: Saito, Zentaro, et al.
Publicado: (2021)

Primary Pulmonary Malignant Melanoma Successfully Treated with Immunotherapy in a 90-Year-Old Patient
por: Fujita, Kohei, et al.
Publicado: (2022)

Successful management of a lung cancer patient harbouring both EGFR mutation and EML4-ALK fusion gene with disseminated intravascular coagulation
por: Fujita, Kohei, et al.
Publicado: (2021)

Pulmonary Lymphangitis Carcinomatosa Mimicking Immunotherapy-Related Interstitial Pneumonitis: A Case Report
por: Imakita, Takuma, et al.
Publicado: (2022)

Impact of COVID‐19 pandemic on lung cancer treatment scheduling
por: Fujita, Kohei, et al.
Publicado: (2020)

Therapy‐related acute myeloid leukemia after chemotherapy in extensive disease‐small cell lung cancer
por: Ueda, Naoko, et al.
Publicado: (2018)

Cutaneous lymphangitis carcinomatosa made cervicofacial oedema intractable in a patient with superior vena cava syndrome
por: Kashihara, Eriko, et al.
Publicado: (2018)

Two cases of cavitary lung cancer with concomitant chronic infectious disease
por: Fujita, Kohei, et al.
Publicado: (2018)

Nivolumab‐induced severe acute kidney injury with a long latent phase in a patient with non‐small‐cell lung cancer: A case report
por: Uchida, Naohiro, et al.
Publicado: (2018)

Decreased handgrip strength can predict lung function impairment in male workers: a cross sectional study
por: Kanai, Makiko, et al.
Publicado: (2020)

Rapidly progressive sarcomatoid malignant mesothelioma of the pleura mimicking pulmonary empyema
por: Fujita, Kohei, et al.
Publicado: (2015)

Pegfilgrastim-Induced Aortitis in a Patient with Small-Cell Lung Cancer Who Received Immunotherapy Combined with Chemotherapy
por: Ito, Takanori, et al.
Publicado: (2023)

Re-immunotherapy with nivolumab plus ipilimumab in advanced non-small cell lung cancer patients previously treated with anti-programmed death-1 and/or anti-programmed death ligand-1 antibodies
por: Imakita, Takuma, et al.
Publicado: (2023)

Nivolumab-induced interstitial lung disease in a patient with gastric cancer
por: Kimura, Akie, et al.
Publicado: (2019)

Interstitial lung disease induced by docetaxel and ramucirumab chemotherapy after nivolumab treatment
por: Okeya, Komugi, et al.
Publicado: (2020)

Natural course of pulmonary hyalinizing granuloma over a decade
por: Fujita, Kohei, et al.
Publicado: (2022)

Successful Rechallenge with Osimertinib following Osimertinib-Induced Ventricular Tachycardia: A Case Report
por: Saito, Zentaro, et al.
Publicado: (2023)

Simultaneous regression of non‐small cell lung cancer and orbital extranodal marginal zone lymphoma with chemoradiotherapy for lung cancer
por: Oi, Issei, et al.
Publicado: (2023)

De Novo SCLC Transformation From KRAS G12C-Mutated Lung Adenocarcinoma With Excellent Response to Sotorasib: A Case Report
por: Ito, Takanori, et al.
Publicado: (2023)

Factors Associated With Efficacy and Nivolumab-Related Interstitial Pneumonia in Non-Small Cell Lung Cancer: A Retrospective Survey
por: Hata, Hiroki, et al.
Publicado: (2020)

Comparison of frailty in patients with nontuberculous mycobacterial lung disease and bronchiectasis: a prospective cohort study
por: Fujita, Kohei, et al.
Publicado: (2022)

2632. Duration of viable SARS-CoV-2 shedding in immunocompromised COVID-19 patients during the widespread vaccination era
por: Kanai, Osamu, et al.
Publicado: (2023)

525. Comparison of the acceptability and safety of molnupiravir in COVID-19 patients aged over and under 80 years
por: Fujita, Kohei, et al.
Publicado: (2023)

Nivolumab: Interstitial pneumonitis: case report
Publicado: (2020)

Delayed pseudoprogression of lung adenocarcinoma accompanied with interstitial lung disease during chemotherapy after nivolumab treatment
por: Kumagai, Toru, et al.
Publicado: (2017)

Safety of Remdesivir for Patients 80 Years of Age or Older with Coronavirus Disease 2019 (COVID-19)
por: Kanai, Osamu, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_shlk8r2o5okpu64jn681rbedqv